Hemophilia Treatment Market – Treatment for Group of Genetic Bleeding Disorders
Hemophilia is a genetic bleeding disorder in which an individual lacks or has low levels of proteins named clotting factors. There are around 13 types of clotting factors that work with blood platelets to help the clotting. There are three forms of hemophilia - A, B, and C. Hemophilia A is the most common form and is caused due to deficiency in factor VIII. Hemophilia B occurs due to deficiency of factor IX and Hemophilia C is caused due to factor XI deficiency. Although Hemophilia is incurable, it can be treated to reduce symptoms and avoid future health complications. Its treatment involves management of bleeding episodes, treatment and rehabilitation of hemophilia synovitis, treatment of factor VIII (FVIII) inhibitors, and prophylaxis.
The global hemophilia treatment market size was valued at US$ 9,412.1 million in 2017 and is expected to witness a robust CAGR of 4.2% over the forecast period (2018 - 2026).
Figure 1. Global Hemophilia Treatment Market (US$ Mn), by Region, 2017
Increasing prevalence of hemophilia diseases worldwide is expected to spur market growth
Increasing demand for hemophilia treatment is expected to be a major factor driving growth of the global hemophilia treatment market over the forecast period. According to National Hemophilia Foundation 2018, total number of hemophilia cases worldwide are not reported so far however it is estimated to affect more than 400,000 individuals. Globally, an estimated 75% of patients with the disease still have no access to treatment or receive inadequate treatment. According to CDC report, Hemophilia A occurs in 1 out of 5,000 live male births. It is nearly four times more common than Hemophilia B. Although currently there is no medication for hemophilia, there are few effective treatments available that may require lifetime infusion of expensive drugs manufactured through recombinant biotechnology or from human plasma. According to CDC funded randomized clinical trial, children who are treated on timely basis to prevent bleeding have less indication of joint damage by age of 6 years. Around 70% hemophilia patients in the U.S. receive multidisciplinary, comprehensive care in a network of federally funded hemophilia treatment centers. High cost associated with recombinant products, serious adverse effects associated with plasma derived products, and limited access to treatment can negatively affect the growth of the global hemophilia market. For instance, risk of infectious disease transmission with plasma derived products can complicate the disease treatment.
Advancing medical knowledge and scientific research to accelerate the market growth
Rise in funding for R&D and advancement in diagnostic technology are expected to prove another booming factor for hemophilia treatment market growth. National Hemophilia Foundation (NHF) award fellowships and grants to support advanced research aimed at finding better cures and treatments for hemophilia. The organization also supports increased federal funding for research and development. Furthermore, gene therapy promises of treating genetic disorders by delivering a functional DNA copy, generally using viral vectors. Many research organizations and biotechnology companies in the gene therapy field are targeting hemophilia for development of advanced treatment options, as it can significantly reduce costs for healthcare providers and patients. Many biotechnology companies are competing to introduce the gene therapy for hemophilia. Spark Therapeutics (U.S.) and uniQure (Netherlands) have the most advanced programs so far.
The major players operating the global hemophilia treatment market include Baxalta, Baxter International, Inc., Biogen Idec, Inc., Bayer AG, CSL Behring, Chugai Pharmaceutical Co., Ferring B.V., Genentech, Inc., Hospira, Inc., Kedrion, Novo Nordisk, Octapharma AG, Pfizer, Inc., Sanofi SA, Shire Plc., and Swedish Orphan Biovitrum AB.
Hemophilia is a genetic disorder in which patient’s blood do not clot normally due to lack of blood-clotting proteins. Hemophilia treatment mainly depends on its severity. The treatment includes timely replacement of the specific clotting factor. Increasing number of hemophilic patient requiring treatment and increased diagnosis rate for Hemophilia are major factors anticipated to drive market growth.
The major factors driving growth of the Hemophilia treatment market is increasing diagnosis rate. In the U.S., majority of Hemophilia cases are diagnosed at a very young age. According to CDC, the median age for diagnosis is one month for individuals with severe symptoms, 8 months for individuals with moderate Hemophilia, and 36 months for people with mild Hemophilia. Hemophilia treatment is more costly and less effective in 25% of individuals with severe type A disease and in the three percent of individuals with severe type B disease who produce neutralizing inhibitors against factor VIII and factor IX, respectively. Various ongoing treatments such as gene therapy can significantly improve the quality of life for Hemophilia patients by eradicating frequent hospital visits and infusions and shifting patients from severe to mild Hemophilia. Increasing R&D investments and product innovations by many industry players is expected to drive growth of the market over the forecast period. For instance, in 2016, FDA approved Bayer’s Kovaltry drug, a low-frequency dosage for Hemophilia A, which requires two to three doses per week.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 22 market data tables and 25 figures on "Global Hemophilia Market - Global forecast to 2026”.
Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:
In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.
Coherent Market Insights desk research is based on a principle set of research techniques:
Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:
Preliminary Data Mining
The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.
Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.
Coherent Statistical model
We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:
Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.
This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:
The primary research is conducted with the ecosystem players including, but not limited to:
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.